Eli Lilly struck an optimistic tone on Wednesday, projecting strong growth through 2026 as demand for its obesity treatments continues to surge. The upbeat outlook stands in sharp contrast to the struggles facing rival Novo Nordisk, which has warned of intensifying price pressure that is weighing heavily on its future sales prospects.
The U.S. drugmaker said it expects revenue to rise by about 25% this year, while Novo Nordisk anticipates its sales could decline by between 5% and 13% in 2026. The diverging forecasts underline how the competitive landscape in weight-loss drugs is increasingly being shaped by consumer demand rather than traditional insurance coverage.
Market Leadership Fuels Investor Confidence
Lilly’s momentum has already translated into market success. Its valuation has climbed past $1 trillion, making it the first pharmaceutical company to reach that milestone. Novo, by contrast, has seen its shares tumble roughly 40% over the past year and recently cautioned investors about what it described as “unprecedented” pricing pressure ahead.
Investors responded positively to Lilly’s outlook, pushing its shares more than 10% higher in early trading. The company overtook Novo last year as the leader in the weight-loss drug market, helped by strong uptake of its injectable treatments.
Oral Weight-Loss Pills Take Center Stage
Competition is now intensifying around oral alternatives. Novo recently launched a pill version of Wegovy at a starting price of $149, ahead of an expected regulatory decision in April on Lilly’s own experimental pill. Lilly plans to roll out its oral weight-loss drug, orforglipron, in the U.S. during the second quarter, with broader international launches expected in 2027, according to Ken Custer, head of cardiometabolic health.
Executives say the early response to oral options reinforces their confidence in the market’s long-term potential, particularly among patients who have been reluctant to use injections.
Strong Financial Performance Backs the Outlook
Lilly forecast 2026 earnings of $33.50 to $35 per share, comfortably above Wall Street expectations. It also projected full-year sales of $80 billion to $83 billion, exceeding analysts’ estimates.
The company’s fourth-quarter results added to the bullish narrative. Profit came in at $7.54 per share, well ahead of expectations, while revenue climbed to $19.3 billion. Analysts noted that the results highlighted how Lilly and Novo, despite competing in similar markets, are facing very different business pressures.
Pricing Pressure Remains a Key Watchpoint
That said, investors remain focused on how Lilly will manage growing pricing headwinds, particularly after reaching an agreement with the U.S. government that includes discounts for Medicare, Medicaid, and cash-pay patients. Management acknowledged that pricing will weigh on growth but emphasized that higher patient volumes should help offset the impact.
Sales of diabetes drug Mounjaro and obesity treatment Zepbound both exceeded expectations in the quarter, driven largely by rising volumes. International demand has also been strong, reinforcing Lilly’s confidence that scale can cushion the effects of lower prices.
Diverging Strategies, Diverging Outcomes
Both Lilly and Novo have moved aggressively into the cash-pay market, cutting prices from roughly $1,000 a month to a few hundred dollars after political pressure to improve affordability. Analysts say Lilly’s updated guidance should ease concerns about whether market expansion can continue to drive growth despite these cuts.
Novo has warned that its own agreement with the U.S. government could trim several percentage points from revenue this year. Lilly, however, believes its expanding patient base and upcoming oral therapies position it to weather the storm far better.
As the weight-loss drug market evolves, the contrast is becoming clearer: while pricing pressure is hitting everyone, Lilly’s scale, pipeline, and execution are helping it pull further ahead—just as Lilly expects robust 2026 growth amid setbacks for weight-loss rival Novo Nordisk.
